The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2024 | HRQoL in patients with transplant-ineligible NDMM treated with Isa-VRd in the IMROZ study
In this video, Meletios Dimopoulos, MD, Kapodistrian University of Athens School of Medicine, Athens, Greece, shares updated results from the IMROZ trial (NCT03319667), highlighting the health-related quality of life (HRQoL) measurements in patients with newly diagnosed multiple myeloma (NDMM) treated with Isa-VRd (isatuximab, bortezomib, lenalidomide, and dexamethasone). This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
